Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBIT: 2010-2025

Historic EBIT for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$94.9 million.

  • Iovance Biotherapeutics' EBIT fell 6.55% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$416.5 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of -$395.3 million for FY2024, which is 14.17% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' EBIT is -$94.9 million, which was up 16.59% from -$113.8 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' EBIT peaked at -$86.6 million during Q4 2024, and registered a low of -$121.3 million during Q4 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median EBIT value was -$110.9 million (recorded in 2023), while the average stood at -$107.8 million.
  • Its EBIT has fluctuated over the past 5 years, first increased by 28.60% in 2024, then fell by 11.64% in 2025.
  • Iovance Biotherapeutics' EBIT (Quarterly) stood at -$121.3 million in 2023, then increased by 28.60% to -$86.6 million in 2024, then dropped by 6.55% to -$94.9 million in 2025.
  • Its EBIT was -$94.9 million in Q3 2025, compared to -$113.8 million in Q2 2025 and -$121.2 million in Q1 2025.